Objective

In Type 1 diabetes (T1D), the body’s immune system mistakenly attacks and destroys pancreatic β-cells, which are responsible for producing insulin. A critical but often overlooked fact is that at the time of clinical diagnosis, many patients still possess between 5% and 50% of their original β-cell mass. However, these remaining cells are often in a "stunned" state: they are alive and present in the pancreas, but they have been rendered non-functional by a toxic, inflammatory environment. This phenomenon is so pronounced that some individuals can face life-threatening complications even when they still have many insulin-producing cells left in their body. The presence of these surviving cells at the onset of the disease opens a vital therapeutic window: if we can stop the immune assault and "wake up" these stunned cells, they may recover enough function to improve blood sugar control and potentially reduce the need for daily insulin injections.
The primary objective of this research project is to determine if this stunned state is permanent or if it can be pharmacologically reversed. Currently, most T1D therapies focus on protecting β-cells from further damage, but there is a major gap in developing treatments that actively restore their ability to secrete insulin after exposure to inflammatory stress. To help resolve this question, our project utilizes two advanced human models that better mimic human pancreatic islets compared to traditional laboratory models. The first uses human islet microtissues (hIsMTs), which are engineered to be uniform and can be cultured in the lab for nearly a month, allowing us to study long-term recovery. The second uses islet-like cells grown from stem cells, representing an unlimited islet cell supply for testing how cells react to various stressors and treatments.
Our collaborative research plan involves inducing this stunned state in the lab with both models and then testing whether specific drugs used to treat other autoimmune diseases can successfully restore insulin production. We will also investigate whether the signaling molecules released by the immune system are enough to stun β-cells even without direct physical contact. Ultimately, the goal is to establish a standardized "New Approach Methodology" (NAM), a reliable and robust screening platform that can be shared with the wider research community and pharmaceutical industry. By creating a way to rapidly identify and validate therapies that restore β-cell function, this work aims to bridge the gap between halting the immune attack and achieving the ultimate clinical goal of insulin independence for people living with T1D.

Background Rationale

In Type 1 diabetes (T1D), the body’s immune system mistakenly attacks and destroys pancreatic β-cells, which are responsible for producing insulin. A critical but often overlooked fact is that at the time of clinical diagnosis, many patients still possess between 5% and 50% of their original β-cell mass. However, these remaining cells are often in a "stunned" state: they are alive and present in the pancreas, but they have been rendered non-functional by a toxic, inflammatory environment. This phenomenon is so pronounced that some individuals can face life-threatening complications even when they still have many insulin-producing cells left in their body.
The presence of these surviving cells creates a vital therapeutic window: if the immune assault can be arrested, these preserved β-cells may recover enough function to improve blood sugar control and potentially reduce the burden of exogenous insulin therapy. While new therapies have successfully demonstrated that immune intervention can delay the onset of clinical T1D, there is currently a significant gap in developing treatments that actively "wake up" the cells and restore their ability to produce insulin after they have been stressed. To find medicines that can reverse this stunned state, scientists need reliable laboratory models that accurately mimic the human pancreatic islets. Traditionally, research has relied on islets from organ donors, but these are difficult to obtain, vary in quality, and often degrade quickly in the lab, which hinders the ability to measure pharmacologically induced recovery.
To solve these limitations, our project utilizes two advanced human models: human islet microtissues (hIsMTs) and islet-like cells grown from induced pluripotent stem cells (iPSCs). The hIsMTs are engineered to be uniform and maintain robust physiological function for at least 28 days, providing the extended lifespan necessary to monitor the kinetics of functional restoration. Complementing this, the iPSC-derived cells provide a renewable and unlimited supply of human islet tissue that is highly amenable to genetic tools, allowing us to study the early stages of the autoimmune process with high mechanistic flexibility.
The rationale for this study is supported by preliminary data showing that these models can successfully recreate the stunned cell phenotype observed in patients. By exposing these models to specific inflammatory agents, we have demonstrated that β-cells can induced to become stunned. This project aims to use these validated models to prove that this stunned state is pharmacologically reversible, specifically by testing the capacity of JAK-STAT pathway inhibitors to restore insulin secretion. Theis class of inhibitors is already in use to treat other autoimmune diseases. By establishing a standardized, ready-to-use screening platform, we hope to empower the global research community to identify new therapies that can restore β-cell function and move patients closer to the ultimate goal of a functional cure and insulin independence.

Description of Project

In Type 1 diabetes (T1D), the body’s immune system mistakenly attacks and destroys pancreatic β-cells, which are responsible for producing insulin. A critical but often overlooked fact is that at the time of clinical diagnosis, many patients still possess between 5% and 50% of their original β-cell mass. However, these remaining cells are often in a "stunned" state: they are alive and present in the pancreas, but they have been rendered non-functional by a toxic, inflammatory environment. This phenomenon is so pronounced that some individuals can face life-threatening complications even when they still have many insulin-producing cells left in their body. The presence of these surviving cells at the onset of the disease opens a vital therapeutic window: if we can stop the immune assault and "wake up" these stunned cells, they may recover enough function to improve blood sugar control and potentially reduce the need for daily insulin injections.
The primary objective of this research project is to determine if this stunned state is permanent or if it can be pharmacologically reversed. Currently, most T1D therapies focus on protecting β-cells from further damage, but there is a major gap in developing treatments that actively restore their ability to secrete insulin after exposure to inflammatory stress. To help resolve this question, our project utilizes two advanced human models that better mimic human pancreatic islets compared to traditional laboratory models. The first uses human islet microtissues (hIsMTs), which are engineered to be uniform and can be cultured in the lab for nearly a month, allowing us to study long-term recovery. The second uses islet-like cells grown from stem cells, representing an unlimited islet cell supply for testing how cells react to various stressors and treatments.
Our collaborative research plan involves inducing this stunned state in the lab with both models and then testing whether specific drugs used to treat other autoimmune diseases can successfully restore insulin production. We will also investigate whether the signaling molecules released by the immune system are enough to stun β-cells even without direct physical contact. Ultimately, the goal is to establish a standardized "New Approach Methodology" (NAM), a reliable and robust screening platform that can be shared with the wider research community and pharmaceutical industry. By creating a way to rapidly identify and validate therapies that restore β-cell function, this work aims to bridge the gap between halting the immune attack and achieving the ultimate clinical goal of insulin independence for people living with T1D.

Anticipated Outcome

The primary anticipated outcome of this research project is to prove that the stunned state of β-cells is not permanent, but a reversible condition that can be treated with the appropriate drugs. By using our advanced human islet models, we expect to demonstrate that specific drugs that are already in use for other autoimmune diseases, can move beyond simply protecting β-cells from damage and actually restore their ability to secrete insulin. This would provide evidence that the functional β-cell mass remaining at the time of a Type 1 diabetes (T1D) diagnosis can be "reawakened" to help regulate blood sugar naturally.
Beyond testing specific drugs, a major outcome will be the establishment of a standardized, ready-to-use screening platform for the global scientific community. By validating this platform across different models (mature, donor-derived human islet microtissues and stem cell-derived islets) we will ensure that any findings are robust and reproducible. This infrastructure will empower other researchers and pharmaceutical companies to systematically screen thousands of novel compounds for their ability to restore β-cell function.
Ultimately, the success of this project aims to shift the focus of T1D therapies from merely slowing down the immune system to actively recovering the body's own insulin-producing capacity. By bridging the gap between halting the immune attack and restoring cellular function, this work seeks to significantly reduce the daily treatment burden for individuals living with T1D. The long-term vision is to provide a clear path towards insulin independence, improving the quality of life for millions of people living with T1D.

Relevance to T1D

The relevance of this research to Type 1 diabetes (T1D) lies in its potential to change how the disease is treated at the moment of diagnosis. T1D is an autoimmune condition in which the body’s own immune system attacks and destroys the insulin-producing β-cells in the pancreas. However, scientific evidence shows that even after a clinical diagnosis, many individuals still have a significant portion (between 5% and 50%) of their original β-cells remaining. These surviving cells are often in a "stunned" state, meaning they are alive but unable to produce the insulin the body needs to regulate blood sugar.
This research is highly relevant because it targets this specific therapeutic window where the remaining β-cells are still present but inactive. While recent medical breakthroughs have succeeded in delaying the progression of T1D by slowing the immune system's attack, they do not yet focus on restoring the function of the cells that have already been damaged but are still alive. By investigating ways to "reawaken" these stunned cells, this project aims to move beyond just protecting pancreatic β-cells and towards actively recovering their natural insulin-producing capacity.
The ultimate goal of this work is to establish a standardized platform that can quickly identify new drugs capable of reversing this cellular stunning. If successful, this approach could lead to therapies that significantly improve blood sugar control and reduce the heavy daily burden of exogenous insulin therapy for people living with T1D.